{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:54:38Z","timestamp":1789901678117,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National High Technology Research and Development Program of China","award":["2012AA02A401"],"award-info":[{"award-number":["2012AA02A401"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00705-016-2817-8","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T21:23:40Z","timestamp":1458336220000},"page":"1517-1526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A novel dengue virus serotype 1 vaccine candidate based on Japanese encephalitis virus vaccine strain SA14-14-2 as the backbone"],"prefix":"10.1007","volume":"161","author":[{"given":"Huiqiang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhushi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"issue":"15","key":"2817_CR1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","volume":"366","author":"CP Simmons","year":"2012","unstructured":"Simmons CP, Farrar JJ, Nguyen VV, Wills B (2012) Dengue. N Engl J Med 366(15):1423\u20131432. doi: 10.1056\/NEJMra1110265","journal-title":"N Engl J Med"},{"key":"2817_CR2","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","volume":"8","author":"MG Guzman","year":"2010","unstructured":"Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E et al (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8:S7\u2013S16. doi: 10.1038\/nrmicro2460","journal-title":"Nat Rev Microbiol"},{"key":"2817_CR3","doi-asserted-by":"crossref","unstructured":"Back AT, Lundkvist A (2013) Dengue viruses\u2014an overview. Infect Ecol Epidemiol 67:171\u2013179, 301\u2013305. doi:10.1038\/nrmicro2460","DOI":"10.1038\/nrmicro2460"},{"key":"2817_CR4","doi-asserted-by":"crossref","unstructured":"Mangold KA, Reynolds SL (2013) A review of dengue fever: a resurging tropical disease. Pediatr Emerg Care 29: 665\u2013669. doi: 10.1097\/PEC.0b013e31828ed30e (quiz 670\u2013671)","DOI":"10.1097\/PEC.0b013e31828ed30e"},{"issue":"Suppl 1","key":"2817_CR5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1179\/2046904712Z.00000000049","volume":"32","author":"T Tantawichien","year":"2012","unstructured":"Tantawichien T (2012) Dengue fever and dengue haemorrhagic fever in adolescents and adults. Paediatr Int Child Health 32(Suppl 1):22\u201327. doi: 10.1179\/2046904712Z.00000000049","journal-title":"Paediatr Int Child Health"},{"key":"2817_CR6","doi-asserted-by":"crossref","unstructured":"Roberts CH, Mongkolsapaya J, Screaton G (2012) Dengue fever: a practical guide. Br J Hosp Med (Lond) 73:C60\u2013C64","DOI":"10.12968\/hmed.2012.73.sup4.C60"},{"key":"2817_CR7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1423-0127-20-37","volume":"20","author":"SW Wan","year":"2013","unstructured":"Wan SW, Lin CF, Wang S, Chen YH, Yeh TM, Liu HS, Anderson R, Lin YS (2013) Current progress in dengue vaccines. J Biomed Sci 20:37. doi: 10.1186\/1423-0127-20-37","journal-title":"J Biomed Sci"},{"key":"2817_CR8","first-page":"31","volume":"12","author":"N Miller","year":"2010","unstructured":"Miller N (2010) Recent progress in dengue vaccine research and development. Curr Opin Mol Ther 12:31\u201338","journal-title":"Curr Opin Mol Ther"},{"key":"2817_CR9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.trsl.2013.03.006","volume":"162","author":"CM Beaumier","year":"2013","unstructured":"Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME (2013) New vaccines for neglected parasitic diseases and dengue. Transl Res 162:144\u2013155. doi: 10.1016\/j.trsl.2013.03.006","journal-title":"Transl Res"},{"key":"2817_CR10","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1016\/j.vaccine.2011.09.114","volume":"30","author":"FX Heinz","year":"2012","unstructured":"Heinz FX, Stiasny K (2012) Flaviviruses and flavivirus vaccines. Vaccine 30:4301\u20134306. doi: 10.1016\/j.vaccine.2011.09.114","journal-title":"Vaccine"},{"key":"2817_CR11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.enzmictec.2012.05.005","volume":"51","author":"HC Lee","year":"2012","unstructured":"Lee HC, Butler M, Wu SC (2012) Using recombinant DNA technology for the development of live-attenuated dengue vaccines. Enzyme Microb Technol 51:67\u201372. doi: 10.1016\/j.enzmictec.05.005","journal-title":"Enzyme Microb Technol"},{"key":"2817_CR12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/QCO.0b013e32834a1b0b","volume":"24","author":"SJ Thomas","year":"2011","unstructured":"Thomas SJ, Endy TP (2011) Critical issues in dengue vaccine development. Curr Opin Infect Dis 24:442\u2013450. doi: 10.1097\/QCO.0b013e32834a1b0b","journal-title":"Curr Opin Infect Dis"},{"key":"2817_CR13","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.3390\/v3122374","volume":"3","author":"WM Wahala","year":"2011","unstructured":"Wahala WM, Silva AM (2011) The human antibody response to dengue virus infection. Viruses 3:2374\u20132395. doi: 10.3390\/v3122374","journal-title":"Viruses"},{"key":"2817_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/tra.12012","volume":"14","author":"J Flipse","year":"2013","unstructured":"Flipse J, Wilschut J, Smit JM (2013) Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans. Traffic 14:25\u201335. doi: 10.1111\/tra.12012","journal-title":"Traffic"},{"key":"2817_CR15","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","volume":"380","author":"A Sabchareon","year":"2012","unstructured":"Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559\u20131567. doi: 10.1016\/S0140-6736(12)61428-7","journal-title":"Lancet"},{"key":"2817_CR16","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4269\/ajtmh.13-0304","volume":"89","author":"GH Dayan","year":"2013","unstructured":"Dayan GH, Garbes P, Noriega F, Izoton de Sadovsky AD, Rodrigues PM, Giuberti C, Dietze R (2013) Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9\u201316 years in Brazil. Am J Trop Med Hyg 89:1058\u20131065. doi: 10.4269\/ajtmh.13-0304","journal-title":"Am J Trop Med Hyg"},{"key":"2817_CR17","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1016\/j.vaccine.2013.08.088","volume":"31","author":"GH Dayan","year":"2013","unstructured":"Dayan GH, Thakur M, Boaz M, Johnson C (2013) Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine 31:5047\u20135054. doi: 10.1016\/j.vaccine.2013.08.088","journal-title":"Vaccine"},{"key":"2817_CR18","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","volume":"384","author":"MR Capeding","year":"2014","unstructured":"Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R et al (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:1358\u20131365. doi: 10.1016\/S0140-6736(14)61060-6","journal-title":"Lancet"},{"key":"2817_CR19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","volume":"372","author":"L Villar","year":"2015","unstructured":"Villar L, Dayan GH, Arredondo-Garc\u00eda JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS et al (2015) Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372:113\u2013123. doi: 10.1056\/NEJMoa1411037","journal-title":"N Engl J Med"},{"key":"2817_CR20","unstructured":"Coudeville L, Baurin N, Vergu E (2015) Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine. doi: 10.1016\/j.vaccine (Epub ahead of print)"},{"key":"2817_CR21","doi-asserted-by":"crossref","unstructured":"Thomas SJ, Rothman AL (2015) Trials and tribulations on the path to developing a dengue vaccine. Vaccine. doi: 10.1016\/j.vaccine.2015.05.095 . (Epub ahead of print)","DOI":"10.1016\/j.vaccine.2015.05.095"},{"key":"2817_CR22","first-page":"836","volume":"17","author":"H Fahimi","year":"2014","unstructured":"Fahimi H, Allahyari H, Hassan ZM, Sadeghizadeh M (2014) Dengue virus type-3 envelope protein domain III; expression and immunogenicity. Iran J Basic Med Sci 17:836\u2013843","journal-title":"Iran J Basic Med Sci"},{"key":"2817_CR23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2012.09.007","volume":"96","author":"CG Noble","year":"2012","unstructured":"Noble CG, Shi PY (2012) Structural biology of dengue virus enzymes: towards rational design of therapeutics. Antiviral Res 96:115\u2013126. doi: 10.1016\/j.antiviral.2012.09.007","journal-title":"Antiviral Res"},{"key":"2817_CR24","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.antiviral.2013.03.008","volume":"98","author":"DA Muller","year":"2013","unstructured":"Muller DA, Young PR (2013) The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker. Antiviral Res 98:192\u2013208. doi: 10.1016\/j.antiviral.2013.03.008","journal-title":"Antiviral Res"},{"key":"2817_CR25","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1016\/j.vaccine.2013.09.030","volume":"31","author":"E Rafferty","year":"2013","unstructured":"Rafferty E, Duclos P, Yactayo S, Schuster M (2013) Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine 31:5798\u20135805. doi: 10.1016\/j.vaccine.2013.09.030","journal-title":"Vaccine"},{"key":"2817_CR26","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3201\/eid1710.101789","volume":"17","author":"SJ Seligman","year":"2011","unstructured":"Seligman SJ (2011) Yellow fever virus vaccine-associated deaths in young women. Emerg Infect Dis 17:1891\u20131893. doi: 10.3201\/eid1710.101789","journal-title":"Emerg Infect Dis"},{"key":"2817_CR27","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","volume":"26","author":"NP Lindsey","year":"2008","unstructured":"Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Slade BA, Barnett ED, Brunette GW, Horan K, Staples JE, Kozarsky PE, Hayes EB (2008) Adverse event reports following yellow fever vaccination. Vaccine. 26:6077\u20136082. doi: 10.1016\/j.vaccine","journal-title":"Vaccine."},{"key":"2817_CR28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4269\/ajtmh.2006.75.333","volume":"75","author":"C Vellozzi","year":"2006","unstructured":"Vellozzi C, Mitchell T, Miller E, Casey CG, Eidex RB, Hayes EB (2006) Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996\u20132004. Am J Trop Med Hyg 75:333\u2013336","journal-title":"Am J Trop Med Hyg"},{"key":"2817_CR29","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","volume":"23","author":"AY Khromava","year":"2005","unstructured":"Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, Cetron MS et al (2005) Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23:3256\u20133263. doi: 10.1016\/j.vaccine.2005.01.089","journal-title":"Vaccine"},{"key":"2817_CR30","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1099\/vir.0.80120-0","volume":"85","author":"Edward Gitau Matumbi Mathenge","year":"2004","unstructured":"Mathenge Edward Gitau Matumbi, del Carmen Maria, Parquet Yasutomo Funakoshi, Houhara Seiji, Wong Pooi Fong, Ichinose Akitoyo, Hasebe Futoshi, Inoue Shingo, Morita Kouichi (2004) Fusion PCR generated Japanese encephalitis virus\/dengue 4 virus chimera exhibits lack of neuroinvasiveness, attenuated neurovirulence, and a dual-flavi immune response in mice. J General Virol 85:2503\u20132513","journal-title":"J General Virol"},{"issue":"Pt 11","key":"2817_CR31","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1099\/vir.0.81909-0","volume":"87","author":"TJ Chambers","year":"2006","unstructured":"Chambers TJ, Jiang X, Droll DA, Liang Y, Wold WS, Nickells J (2006) Chimeric Japanese encephalitis virus\/dengue 2 virus infectious clone: biological properties, immunogenicity and protection against dengue encephalitis in mice. J Gen Virol. 87(Pt 11):3131\u20133140","journal-title":"J Gen Virol."},{"key":"2817_CR32","doi-asserted-by":"crossref","first-page":"13694","DOI":"10.1128\/JVI.00931-13","volume":"87","author":"XF Li","year":"2013","unstructured":"Li XF, Deng YQ, Yang HQ, Zhao H, Jiang T, Yu XD, Li SH, Ye Q, Zhu SY, Wang HJ, Zhang Y, Ma J, Yu YX, Liu ZY, Li YH, Qin ED, Shi PY, Qin CF (2013) A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates. J Virol 87:13694\u201313705. doi: 10.1128\/JVI.00931-13","journal-title":"J Virol"},{"key":"2817_CR33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virusres.2014.07.017","volume":"191","author":"Z Li","year":"2014","unstructured":"Li Z, Yang H, Yang J, Lin H, Wang W, Liu L, Zhao Y, Liu L, Zeng X, Yu Y, Li Y (2014) Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone. Virus Res 191:10\u201320. doi: 10.1016\/j.virusres.2014.07.017","journal-title":"Virus Res"},{"key":"2817_CR34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/vim.2008.0007","volume":"21","author":"JT Roehrig","year":"2008","unstructured":"Roehrig JT, Hombach J, Barrett AD (2008) Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21:123\u2013132. doi: 10.1089\/vim.2008.0007","journal-title":"Viral Immunol"},{"key":"2817_CR35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/1535370212473703","volume":"238","author":"K Chokephaibulkit","year":"2013","unstructured":"Chokephaibulkit K, Perng GC (2013) Challenges for the formulation of a universal vaccine against dengue. Exp Biol Med (Maywood) 238:566\u2013578. doi: 10.1177\/1535370212473703","journal-title":"Exp Biol Med (Maywood)"},{"key":"2817_CR36","first-page":"305","volume":"4","author":"KB Clark","year":"2013","unstructured":"Clark KB, Onlamoon N, Hsiao HM, Perng GC, Villinger F (2013) Can non-human primates serve as models for investigating dengue disease pathogenesis? Front Microbiol 4:305. doi: 10.3389\/fmicb.2013.00305","journal-title":"Front Microbiol"},{"key":"2817_CR37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/v4010062","volume":"4","author":"S Zompi","year":"2012","unstructured":"Zompi S, Harris E (2012) Animal models of dengue virus infection. Viruses 4:62\u201382. doi: 10.3390\/v4010062","journal-title":"Viruses"},{"key":"2817_CR38","doi-asserted-by":"crossref","unstructured":"Suzarte E, Marcos E, Gil, L, Vald\u00e8s I, Lazo L, Ramos Y , P\u00e8rez Y, Falc\u00f3n V, Romero Y, Guzm\u00f3n MG, Gonz\u00e1lez S, Kouri J, Guill\u00e8n G, Hermida L (2014) Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. Arch Virol 159:1629\u20131640. doi: 10.1007\/s00705-013-1956-4","DOI":"10.1007\/s00705-013-1956-4"},{"key":"2817_CR39","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1128\/JVI.02575-06","volume":"81","author":"HC Chen","year":"2007","unstructured":"Chen HC, Hofman FM, Kung JT, Lin YD, Wu-Hsieh BA (2007) Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J Virol 81:5518\u20135526. doi: 10.1128\/JVI.02575-06","journal-title":"J Virol"},{"key":"2817_CR40","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.virol.2005.04.042","volume":"338","author":"MV Paes","year":"2005","unstructured":"Paes MV, Pinh\u00e3o AT, Barreto DF, Costa SM, Oliveira MP, Nogueira AC, Takiya CM, Farias-Filho JC, Schatzmayr HG, Alves AM, Barth OM (2005) Liver injury and viremia in mice infected with dengue-2 virus. Virology 338:236\u2013246","journal-title":"Virology"},{"key":"2817_CR41","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","volume":"78","author":"F Guirakhoo","year":"2004","unstructured":"Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, Brown N, Brandler S, Fournier C, Barrere B, Rizvi F, Travassos A, Nichols R, Trent D, Monath T (2004) Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78:4761\u20134775. doi: 10.1128\/JVI.78.9.4761-4775","journal-title":"J Virol"},{"key":"2817_CR42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/viro.2002.1462","volume":"298","author":"F Guirakhoo","year":"2002","unstructured":"Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP (2002) Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298:146\u2013159. doi: 10.1006\/viro.2002.1462","journal-title":"Virology"},{"issue":"6","key":"2817_CR43","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1128\/JVI.77.6.3655-3668.2003","volume":"77","author":"TJ Chambers","year":"2003","unstructured":"Chambers TJ, Liang Y, Droll DA et al (2003) Yellow fever virus\/dengue-2 virus and yellow fever virus\/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J Virol 77(6):3655\u20133668","journal-title":"J Virol"},{"key":"2817_CR44","unstructured":"WHO (2011) Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Proposed replacement of annex 2. In: WHO technical report series, No. 979"},{"key":"2817_CR45","unstructured":"WHO (2013) Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Replacement of annex 1, TRS, 878. In: Technical report series 978, annex 3. WHO, Geneva"},{"key":"2817_CR46","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1128\/JVI.75.16.7290-7304.2001","volume":"75","author":"F Guirakhoo","year":"2001","unstructured":"Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP (2001) Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75:7290\u20137304. doi: 10.1128\/JVI.75.16.7290-7304.2001","journal-title":"J Virol"},{"key":"2817_CR47","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1128\/JVI.74.12.5477-5485.2000","volume":"74","author":"F Guirakhoo","year":"2000","unstructured":"Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP (2000) Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74:5477\u20135485. doi: 10.1128\/JVI.74.12.5477-5485.2000","journal-title":"J Virol"},{"key":"2817_CR48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/1348-0421.12140","volume":"58","author":"L Lazo","year":"2014","unstructured":"Lazo L, Izquierdo A, Suzarte E, Gil L, Vald\u00e9s I, Marcos E, \u00c1lvarez M, Romero Y, Guzm\u00e1n MG, Guill\u00e9n G, Hermida Cruz L (2014) Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus. Microbiol Immunol 58:219\u2013226. doi: 10.1111\/1348-0421.12140","journal-title":"Microbiol Immunol"},{"key":"2817_CR49","doi-asserted-by":"crossref","first-page":"e25685","DOI":"10.1371\/journal.pone.0025685","volume":"6","author":"SM Costa","year":"2011","unstructured":"Costa SM, Yorio AP, Gon\u00e7alves AJ, Vidale MM, Costa EC, Mohana-Borges R, Motta MA, Freire MS, Alves AM (2011) Induction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines. PLoS One 6:e25685. doi: 10.1371\/journal.pone.0025685","journal-title":"PLoS One"},{"key":"2817_CR50","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.vaccine.2010.01.022","volume":"28","author":"DE Clements","year":"2010","unstructured":"Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, Peters ID, Leung J, Weeks-Levy C, Nakano ET, Humphreys T (2010) Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28:2705\u20132715. doi: 10.1016\/j.vaccine.2010.01.022","journal-title":"Vaccine"},{"key":"2817_CR51","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1128\/JVI.00512-07","volume":"81","author":"Laura J White","year":"2007","unstructured":"White Laura J, Parsons Melissa M, Whitmore Alan C, Williams Brandon M, de Silva Aravinda, Johnston Robert E (2007) An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J Virol 81:10329\u201310339. doi: 10.1128\/JVI.00512-07","journal-title":"J Virol"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-016-2817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00705-016-2817-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-016-2817-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T18:35:36Z","timestamp":1567708536000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00705-016-2817-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["2817"],"URL":"https:\/\/doi.org\/10.1007\/s00705-016-2817-8","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,15]]}}}